Sign in
Taking people in United StatesPhase 1

Tests engineered immune cells against advanced melanoma skin cancer

Tests modified immune T cells, given at rising doses, in adults with advanced melanoma.

Key facts

Who runs it
Loyola University
Where
Maywood, United StatesSee the site
Trial code
Registry title
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Status
Recruiting
Phase
Phase 1
People taking part
18 people, planned
Started
Feb 2015
Expected to end
Sept 2028
Type of study
Interventional
Treatments tested
  • Escalating Doses
Record updated
12 March 2018

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with metastatic melanoma whose tumour is positive for both tyrosinase and HLA-A2. It tests engineered T cells made from the patient's own cells.

Age
18 to 89 years
Sex
All sexes
Disease stage
Metastatic melanoma that can be seen on exam or scan. Tumour must be positive for tyrosinase and HLA-A2. Heart ejection fraction must be above 50 percent. ECOG performance status must be 0 or 1.
Earlier treatment
After anti-CTLA-4 antibody: at least 6 weeks since the last dose and the tumour has grown. After anti-PD-1 or anti-PD-L1 antibody: at least 4 weeks since the last dose and the tumour has grown. People with a V600E mutation must have failed or refused an approved BRAF or MEK inhibitor. Earlier IL-2 treatment is allowed. No chemotherapy or investigational treatment in the 4 weeks before the start.
Biomarker or test result
Melanoma must be positive for both tyrosinase and HLA-A2 on a biopsy.

Main reasons for not taking part

  • Pregnant or nursing women
  • Brain metastases with active disease, or active within the last three months and not controlled by surgery or radiotherapy
  • Taking steroids for disease control or pain
  • Known HIV, HBV or HCV infection
  • Earlier immunotherapy targeting tyrosinase, or immunotherapy combined with non-myeloablative chemotherapy

The registry criteria, word for word

Show all 28 criteriaShow less

Who can take part

  • Patients must have a diagnosis of metastatic melanoma which is evaluable either clinically or radiologically
  • Patients must be 18 years of age or older
  • Patients must consent to be in the study and must have signed and dated an approved consent form, which conforms to federal and institutional guidelines
  • Patients must have a performance status (PS) of 0 or 1 ECOG PS scale
  • Patients must have the ability to provide written informed consent prior to study specific screening procedures, with the understanding that the patient has the right to withdraw from the study at any time
  • Patients melanoma must be positive for both tyrosinase and HLA-A2 pathologic review from FNA, core or excisional biopsy of lesion
  • Cardiac ejection fraction greater than 50 percent as determined by screening echocardiogram
  • Patients that have undergone treatment with anti-CTLA-4, Cytotoxic T-Lymphocyte Antigen 4, antibody must have at least 6 weeks from last dose of CTLA-4 antibody and evidence of tumor progression before they can be enrolled into this study
  • Patients that have undergone treatment with anti-PD-1, Programmed Death Receptor 1, Blockade or anti-PD-L1 antibody must have at least 4 weeks from last dose of antibody and evidence of tumor progression before they can be treated in this study
  • Patients with V600E mutations are eligible if they have failed an approved BRAF inhibitor or MEK inhibitor therapy or have refused treatment with an approved BRAF inhibitor or MEK inhibitor
  • Patients treated with prior Interleukin-2 (IL-2) are eligible
  • Sufficient cardiopulmonary reserve for IL-2 per institutional guidelines

Who cannot take part

  • Patients with a history metastatic melanoma involving the brain will be excluded if they have active disease or have had active disease within the prior three months that was not controlled with surgery or radiotherapy
  • Patients whose BRAF V600 mutation status is unknown should undergo an attempt to determine this information, patients who have a BRAF V600 mutation and are responding to BRAF with or without MEK inhibitor therapy, or have a BRAF V600 mutation and have not been offered the option of receiving BRAF with or without MEK inhibitor therapy for the treatment of their melanoma are excluded
  • Patients that have undergone immunotherapy targeting tyrosinase
  • Patients that have undergone immunotherapy in combination with non-myeloablative chemotherapy
  • Patients should not have any evidence of active or uncontrolled infection requiring treatment with antibiotics
  • Patients who have received any chemotherapy or investigational treatment within 4 weeks of study start
  • Patients taking steroids for disease control or pain management
  • No prior malignancy is allowed except for the following- adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated Stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease-free for two years
  • Any severe or poorly controlled systemic disease, for example hypertension, clinically significant cardiovascular, pulmonary, or metabolic disease, disorders of wound-healing, ulcer or bone fracture
  • Known infection with HIV, HBV, or HCV
  • Known hypersensitivity to any of the components of the study drugs
  • Any of the following abnormal laboratory values Absolute neutrophil count less than 1.5 x 10\^9/L Platelet count less than 100 x 10\^9/L Serum bilirubin greater than 1.5 x upper limit of normal ULN Serum ALT, AST greater than 2.5 x ULN Serum ALP greater than 2 x ULN Serum Albumin less than 2.5 g dL International Normalized Ratio, INR greater than 1.5 Serum creatinine calculated creatinine clearance by the method of Cockcroft and Gault, less than 50mL min
  • Special classes of subjects such as fetuses, pregnant women, children, prisoners, institutionalized individuals, or others who are likely to be vulnerable
  • ECOG performance status of 2 or greater
  • Patients must not be pregnant or nursing because of the potentially harmful effects of these agents on a developing fetus. Women or men of reproductive potential must have agreed to use an effective contraceptive method
  • Patients assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 89 years old?

Where in United States

  • Loyola University Medical CenterMaywood, United StatesContact: Michael Nishimura, PhDTaking people

About the trial

What the trial wants to find out

Phase I clinical trial to determine the Phase II dose of autologous TIL 1383I TCR gene modified T Cells using a retrovirus. This is a novel National Cancer Institute (NCI) funded investigator initiated therapy for patients with advanced melanoma.

The group in the trial

  • Escalating DosesTreatment being tested

    Three patients will be treated at the first \& each subsequent dose level. Patients will be observed for 30 days post T cell infusion. If there was one DLT in the first 3 patients, an additional 3 patients will be treated at that level. If no additional DLTs are observed (for a total of 1 DLT in 6 patients) then the dose will be escalated. If two patients in the first 3 patients at a dose level experience a DLT, the dose will be de-escalated to the previous level \& an additional 3 patients will be enrolled at that level if 6 have not yet been treated at that level. The maximum tolerated dose (MTD) is defined as the highest dose at which 0 or 1 patient in six has experienced a DLT. If 2 or 3 patients in the first 3 patients experience a DLT at the first dose level, the study will terminate.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes: A Phase 1b Study
Plain-language title
Tests engineered immune cells against advanced melanoma skin cancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT02870244, who can take part
Record updated
12 March 2018